AstraZeneca Launches New Fixed-Dose Combination Therapy for Adults with Type 2 Diabetes in China

11Month 22AstraZeneca announces Andasutra®(General name: Dapagliflozin Metformin Sustained-Release Tablets) This compound preparation for type 2 diabetes has officially been launched in China.Dapagliflozin Metformin Sustained-Release Tablets are aCompound preparation, itsCombines two complementary antihyperglycemic drugs: dapagliflozin (trade name: Forxiga), a sodium-glucose cotransporter-2 (SGLT2) inhibitor,Previously approved in China for the treatment of adult type 2 diabetes,Symptomatic Chronic Heart FailureAndChronic Kidney Disease, andMetformin Hydrochloride Extended-Release Tablets, a once-daily oral biguanide tablet.As the only compound preparation in China that is taken once daily at a fixed dose, containing an SGLT2 inhibitor and an extended-release metformin hydrochloride agent,Dapagliflozin Metformin Sustained-Release TabletsProvides a first-line treatment option for improving blood glucose control in patients with type 2 diabetes.